Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Positive Visx says Icahn has "nothing new"

This article was originally published in Clinica

Executive Summary

Ophthalmic laser company Visx says its earnings-per-share for the first quarter will be $0.20-$0.21 - compared with analysts' expectations of $0.18 - due in part to a sequential 23% increase in licensing revenues. The good news compares with a profit warning for the previous quarter (see Clinica No 940, p 14). At the same time, the company has urged shareholders not to accept financier Carl Icahn's proxy nominees for the board.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts